Journal of Cell Biology Impact Factor

The 6.4 JIF places JCB in the Q1 tier of cell biology, though at position 48/204 it sits in the lower portion of Q1. The five-year JIF (7.2) running above the two-year number shows some long-tail citation value, consistent with a journal that publishes mechanistic work with lasting relevance.

The historical context matters: JCB was a considerably higher-impact journal a decade ago (JIF above 10). The decline reflects the journal's position being squeezed between Nature Cell Biology and the growing Cell Press family (Cell Reports, Developmental Cell) on one side, and open-access alternatives on the other. It's not that JCB's quality has dropped. It's that the competitive landscape has shifted.

The cited half-life of 16.2 years is remarkably long, one of the highest in cell biology. That number tells you JCB's archive retains value for an exceptionally long time. Classic JCB papers on cell division, membrane trafficking, and cytoskeletal dynamics are still routinely cited. The journal publishes the kind of cell biology that becomes textbook material.

The gradual decline from ~9 in 2018-2019 to 6.4 in 2024 reflects the shifting competitive landscape rather than a quality drop. JCB's exceptionally long cited half-life of 16.2 years confirms that the journal's archive retains lasting value.

• whether your imaging and quantitative data meet JCB's standards

• how the Rockefeller University Press editorial process compares to Cell Press

• how hiring committees weigh JCB against Cell Reports in your field

• how long peer review will take

• whether the cell biology angle is strong enough for this audience

For manuscripts targeting Journal of Cell Biology, three patterns account for most of the desk rejections we see.

Mechanistic papers without strong imaging.

JCB has a specific editorial identity built around imaging-rich, visually rigorous cell biology. The journal was an early adopter of strict image integrity standards and its reviewers actively evaluate microscopy data quality, quantification approaches, and the visual logic of the paper's cell biological argument.

We see manuscripts with solid biochemical or molecular mechanistic data that do not have the imaging component JCB specifically values, papers where the cell biology is demonstrated through blots, IP experiments, and flow cytometry without the microscopy that makes the work visually compelling. Those papers are better targeted at EMBO Journal, Cell Reports, or Molecular and Cellular Biology. At JCB, the imaging needs to carry part of the scientific argument, not just illustrate it.

Papers outside JCB's core cell biology areas. JCB has deep institutional identity in specific areas: cell division, membrane trafficking, organelle dynamics, cytoskeletal biology, and cell motility. Papers in these areas benefit from the journal's editorial community memory and reviewer expertise in those systems.

We see submissions in areas that are tangential to JCB's core, papers in signal transduction, gene expression, or metabolism that are framed as cell biology but do not have the cell-structural or cell-organizational logic that JCB reviewers are trained to evaluate. The journal's fit is narrower than the "cell biology" category implies, and papers that are really molecular biology or biochemistry with a cell biology angle will face skepticism at triage.

Over-reliance on supplementary figures. JCB's editorial tradition values papers where the main figures tell a coherent, complete story. We see submissions with 5-6 main figures and 15-20 supplementary figures, which is often a signal that the core argument is not disciplined enough for JCB's standards. Reviewers at this journal are attentive to whether the supplement is doing work that belongs in the main text, or whether it is genuinely supporting detail.

A paper where the reader needs the supplementary data to understand the main claim will face requests to reorganize, and that reorganization often reveals that the story is thinner than the total figure count suggests.

JCB editors look for cell biology that combines mechanistic insight with strong visual and quantitative data. The journal has historically been the home for:

• cell division and mitosis mechanisms

• membrane trafficking and organelle dynamics

• cytoskeletal biology and cell motility

• quantitative microscopy and imaging-driven cell biology

Papers that are primarily biochemical or molecular without a clear cell biology angle tend to be redirected. The journal values seeing cells do things, and the imaging data needs to be publication-quality. JCB was one of the first journals to adopt strict image integrity standards, and that commitment to visual rigor remains central to its identity.

Submit if:

• the paper is imaging-rich cell biology with clear mechanistic insight

• the visual data is strong, quantitative, and central to the story

• JCB's editorial tradition in your cell biology subfield fits the work

• you value the Rockefeller University Press brand in the cell biology community

Think twice if:

• Nature Cell Biology is a realistic higher-impact target

• Cell Reports would provide broader Cell Press visibility at a similar JIF

• the work lacks the imaging or visual biology strength JCB specifically values

• EMBO Journal would better serve molecular or cell biology that isn't imaging-focused

JCB is the kind of journal where field memory matters. The impact factor alone can make it look like a generic mid-tier option, but that is not how many cell biologists actually read it. The more practical question is whether the manuscript benefits from JCB's identity as a rigorous, imaging-literate, mechanistic cell-biology venue rather than from a broader journal with a slightly different audience.

That makes this page most useful for shortlist decisions, not vanity ranking. Authors comparing JCB with Cell Reports, EMBO Journal, or Nature Cell Biology should ask what kind of community recognition they need and whether the paper's visual and quantitative strengths are central enough for JCB to be the smarter fit.

• Nature Cell Biology impact factor

• Cell Reports impact factor

• EMBO Journal impact factor

• Developmental Cell impact factor

JCB's current number makes more sense when you read it as a long-run trend rather than a one-year scoreboard. The journal has moved from older double-digit years into a lower but still respected specialist tier as top cell-biology attention spread across Nature titles, Cell Press titles, and newer open-access options. That shift matters because it explains why the metric can look modest while the journal's field memory and niche authority remain strong.

Journal of Cell Biology rejects roughly 75-80% of submissions, but its 6.4 IF does not reflect that selectivity because cell biology as a category has migrated toward broader-scope journals (Cell Reports, eLife, Nature Communications) over the past five years. JCB's selectivity is now decoupled from its IF position. The 6.4 reads correctly as a specialist signal: this is the imaging-rich, mechanism-first, quantitative cell biology venue.

Comparing JCB's 6.4 to Cell (66) or Developmental Cell (10.7) on IF alone misses what JCB is actually selecting for.

What 6.4 cannot show about a JCB submission: editors prioritize imaging-quality, quantitative single-cell measurements, and durable mechanistic conclusions over breadth or general appeal. The friction submissions are descriptive cell-biology surveys without mechanism and high-throughput screens without follow-up validation. Subfield prestige concentrates in cytoskeleton biology, membrane trafficking, and quantitative microscopy where JCB has been the de facto standard for decades.

Before submitting, a JCB submission readiness check can assess whether your manuscript fits the journal's actual editorial scope and mechanistic evidence bar.